Wells Fargo & Company Issues Positive Forecast for DexCom (NASDAQ:DXCM) Stock Price

DexCom (NASDAQ:DXCM) had its target price upped by Wells Fargo & Company from $85.00 to $90.00 in a report published on Friday morning,Benzinga reports. They currently have an overweight rating on the medical device company’s stock.

A number of other brokerages have also recently commented on DXCM. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 10th. Bank of America lowered their target price on DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. William Blair upgraded DexCom to a “strong-buy” rating in a report on Friday, May 15th. UBS Group set a $96.00 price target on shares of DexCom and gave the company a “buy” rating in a research report on Tuesday. Finally, Truist Financial set a $93.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $88.12.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $83.45 on Friday. The firm has a market capitalization of $32.20 billion, a P/E ratio of 32.98, a P/E/G ratio of 1.23 and a beta of 1.45. The firm’s 50-day moving average price is $73.14 and its 200-day moving average price is $69.20. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. DexCom has a 1-year low of $54.11 and a 1-year high of $87.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The company had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period last year, the business posted $0.48 EPS. The firm’s revenue for the quarter was up 13.1% compared to the same quarter last year. Equities research analysts anticipate that DexCom will post 2.57 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin R. Sayer sold 26,759 shares of DexCom stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $72.00, for a total transaction of $1,926,648.00. Following the transaction, the insider owned 382,482 shares of the company’s stock, valued at $27,538,704. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jon Coleman sold 4,912 shares of the company’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total value of $358,576.00. Following the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. This trade represents a 4.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 98,506 shares of company stock valued at $7,205,258. 0.28% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently bought and sold shares of the company. Reflection Asset Management bought a new stake in shares of DexCom in the 4th quarter worth $25,000. Ascentis Independent Advisors bought a new position in shares of DexCom during the first quarter valued at about $25,000. MCF Advisors LLC bought a new position in shares of DexCom during the fourth quarter valued at about $32,000. Wellington Grp LLC boosted its holdings in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after purchasing an additional 475 shares during the last quarter. Finally, DV Equities LLC purchased a new position in DexCom during the fourth quarter worth about $36,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom News Summary

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.